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Abstract
A treatment regime is a deterministic function that dictates personalized treat-
ment based on patients’ individual prognostic information. There is a fast-growing
interest in finding optimal treatment regimes to maximize expected long-term clin-
ical outcomes of patients for complex diseases, such as cancer and AIDS. For many
clinical studies with survival time as a primary endpoint, a main goal is to maximize
patients’s survival probabilities given treatments. In this article, we first propose two
nonparametric estimators for survival function of patients following a given treat-
ment regime. Then, we derive the estimation of the optimal treatment regime based
on a value-based searching algorithm within a set of treatment regimes indexed
by parameters. The asymptotic properties of the proposed estimators for survival
probabilities under derived optimal treatment regimes are established under suitable
regularity conditions. Simulations are conducted to evaluate the numerical perfor-
mance of the proposed estimators under various scenarios. An application to an
AIDS clinical trial data is also given to illustrate the methods.
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2
1 Introduction
For many complex diseases, such as cancer, AIDS and mental disorder, there is generally
not a uniformly best treatment for all patients. Different patients may favor different
treatments, due to individual heterogeneity. For example, in the AIDS Clinical Trials
Group Study 175 (Hammer et al., 1996), a primary endpoint of interest is the time to
having a larger than 50% decline in the CD4 count, or progressing to AIDS, or death,
whichever comes first. We are interested in comparing two treatments: zidovudine plus
didanosine (denoted as treatment 1) and zidovudine plus zalcitabine (denoted as treatment
0). We observe that the zidovudine plus zalcitabine treatment is more favorable to younger
HIV patients comparing with the zidovudine plus didanosine treatment. To see this, we
divide patients into two groups according to the median age of patients, which is 34 in
the data. We then plot the treatment specific Kaplan-Meier curves within each age strata,
which is given in Figure 1. From the plot, it can be clearly seen that the zidovudine plus
zalcitabine treatment group has almost uniformly larger survival probabilities than the
zidovudine plus didanosine treatment group for younger patients with age ≤ 34, while
the zidovudine plus didanosine treatment group has uniformly larger survival probabilities
than the zidovudine plus zalcitabine treatment group for older patients with age > 34.
This raises a practically important question on how to appropriately use patients’
individual prognostic information when assigning treatments to maximize an expected
long-term clinical outcome of interest, such as t-year survival probability. The deriva-
tion of optimal individualized treatment regimes, which are a set of treatment decision
rules based on patients’ individual prognostic information, have received a lot of attention
recently, especially for complex diseases such as cancer, AIDS and mental disorder. In ad-
dition, for many complex diseases, treatments may be given sequentially at multiple time
points. Then a treatment decision rule at a given time point may depend on the base-
line prognostic factors, previous assigned treatments and all the intermediate outcomes
observed in the past, which results a dynamic treatment regime. There is a fast develop-
ment of statistical methods for estimating the optimal dynamic treatment regimes. For
example, Q-learning (Watkins, 1989; Watkins and Dayan, 1992; Murphy, 2005; Zhao et al.,
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Figure 1: Treatment specific Kanplan-Meier curves by age.
2009) and A-learning (Murphy, 2003; Robins, 2004) are two popular backward induction
methods for estimating optimal dynamic treatment regimes. The former is primarily a
parametric approach which builds regression models for the so-called Q functions, while
the latter is a semiparametric approach which models contrast functions. In addition, A-
learning enjoys the double robustness property, i.e. the corresponding estimating equations
are asymptotically unbiased when either the baseline mean model or the propensity score
model is correctly specified. More recently, Zhang et al. (2012) formularized the problem
in a missing data framework and proposed inverse propensity score weighted (IPSW) and
augmented IPSW estimators for the expected potential outcome following a specified treat-
ment regime, namely the value function. Then, they proposed to search the best treatment
regime in a pre-specified class of treatment decision rules indexed by parameters to maxi-
mize the value function. Such a value-function based optimization method is robust in the
sense that it only requires to specify the class of intended treatment regimes but not the
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models for the Q-functions or contrast functions. In addition, Zhao et al. (2012) recast the
estimation method of Zhang et al. (2012) in a classification framework and proposed an
outcome-weighted learning method to estimate the optimal treatment regime by outcome
weighted support vector machines. Zhang et al. (2013) extended the value-function based
optimization method to estimate the optimal dynamic treatment regime, mainly for two
treatment decision time points.
When the outcome of interest is survival time as seen in many clinical trails or ob-
servational studies, there is less development for estimation of optimal treatment regimes
to maximize patients’ survival probabilities given treatments. To our best knowledge,
most literatures are focusing on comparing two given treatment regimes. Based on ob-
servational experiments with imbalanced treatment assignment, Chen and Tsiatis (2001)
and Zhang and Schaubel (2012) compare the restricted mean survival time for two simple
regimes, either giving everyone treatment 1 or giving everyone treatment 0. In addition,
Bai et al. (2013) proposed doubly-robust estimators for treatment-specific survival prob-
abilities based on observational data with stratified sampling. On the other hand, Uno
et al. (2007) make use of patients’ baseline information to predict their risk levels of de-
veloping the event of interest at a pre-specified time, i.e. t-year survival. Then based
on the predicted risk levels, patients are recommended for different therapies accordingly.
However, this generally can not lead to an optimal treatment regime that maximizes pa-
tients’ t-year survival probabilities. Most recently, Goldberg and Kosorok (2012) developed
a Q-learning algorithm for censored survival data for estimating optimal dynamic treat-
ment regimes and derived its associated finite sample bounds on the generalization error
of the policy learned by the algorithm. This approach requires to build a proper regres-
sion model for survival times that incorporates both the baseline covariate effects and
treatment-covariate interaction effects, which may not be easy in practical applications.
In this article, we propose a value-function based policy search method to estimate the
optimal treatment regime that leads to the maximal t-year survival probability. Specifi-
cally, we first develop two Kaplan-Meier-type estimators for the survival function of pa-
tients following a given treatment regime. Then we search the best treatment regime
within a class of specified regimes to maximize the associated t-year survival probability.
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Since the estimated t-year survival probability following a given treatment regime is a very
discrete function of parameters, the direct maximization may be challenging and the re-
sulting estimators may suffer from the numerical instability. To improve the finite sample
performance of the estimators, we introduce the kernel smoothing technique to smooth the
value function at a proper rate. Both numerical and theoretical properties of the proposed
estimators for the t-year survival probability following the estimated optimal treatment
regime are investigated. In addition, we generalize the proposed method to estimating
optimal dynamic treatment regimes and use the case with two treatment decision time
points as an illustration.
The rest of the article is organized as follows. We describe our methodology for esti-
mating optimal treatment regimes with a single decision point and multiple decision points
in Section 2 and 3, respectively. The asymptotic properties of the proposed estimators are
given in Section 4. Section 5 studies the finite sample performance of the proposed estima-
tors. Section 6 considers an application to a dataset from the AIDS Clinical Trials Group
Study 175 to further illustrate our method. We conclude our work with some discussions
in Section 7. All the proofs are delegated to the Appendix.
2 Estimation of Optimal Treatment Regime for a Sin-
gle Decision Time Point
2.1 Notation and Assumption
Consider a study with two treatment options A = {0, 1} given at the baseline. For
the ith patient, i = 1, · · · , n, let Xi denote the p-dimensional vector of baseline covari-
ates and Ai denote the actual treatment received by the patient. In addition, let Ti
be the associated continuous survival time of interest, with conditional survival function
ST (t|a,x) ≡ P (Ti > t|Ai = a,Xi = x) and the corresponding conditional cumulative haz-
ard function denoted by ΛT (t|a,x), where a = 0/1. Let Ci denote the right censoring time
for patient i. The observed data for n independently and identically distributed patients
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consist of {(Xi, Ai, T˜i, δi), i = 1, . . . , n}, where T˜i = min{Ti, Ci} and δi = I{Ti ≤ Ci}.
Furthermore, we also observe the counting process Ni(t) = I(T˜i ≤ t, δi = 1) and the at
risk process Yi(t) = I(T˜i ≥ t).
A treatment regime is a deterministic function that maps X to A. For simplicity,
we assume the regimes of interest are from G = {gη : gη(X) = I{ηTX˜ ≥ 0},η ∈
Rp+1, ||η|| = 1}, where X˜ = (1,XT )T . However, the proposed method also applies to
any other G that can be indexed by finite-dimensional parameters. Denote the potential
survival time of a patient if he/she were given treatment a, which may be contrary to
fact, as T ∗(a). Accordingly, define the potential counting process N∗(a; t) and at risk
process Y ∗(a; t) under treatment a, where N∗(a; t) = I{min(T ∗(a), C) ≤ t, T ∗(a) ≤ C}
and Y ∗(a; t) = I{min(T ∗(a), C) ≥ t}. If a patient follows a given regime gη, we can write
the corresponding potential survival time as T ∗(gη) = T ∗(1)gη + T ∗(0)(1 − gη), whose
survival function is given by S∗(t;η) = EX [P{T ∗(gη(X)) > t|X}], as well as the potential
counting process N∗(gη; t) = N∗(1; t)gη+N∗(0; t)(1−gη) and the potential at risk process
Y ∗(gη; t) = Y ∗(1; t)gη+Y ∗(0; t)(1−gη). We are interested in finding the optimal treatment
regime in G that maximizes t-year survival probability, that is goptη (x) ≡ g(x;ηopt), where
ηopt = arg max||η||=1 S∗(t;η). Here t is a pre-determined time point, such as 3-year.
To find the optimal treatment regime, we first derive consistent estimators of S∗(u;η)
for any u. To do this, we make the following uninformative censoring assumption: C
is independent of {T ∗(1), T ∗(0)} given A and X. Let SC(t|a, ,x) denote the survival
function of the censoring time given A = a and X = x. If we were able to observe the
gη-specified potential counting processes N
∗
i (gη; s)’s and at risk processes Y
∗
i (gη; s)’s, an
intuitive estimator for S∗(u;η) is to consider an inverse probability censoring weighted
Kaplan-Meier estimator, specifically,
Ŝ∗(u;η) =
∏
s≤u
(
1−
∑n
i=1[dN
∗
i {gη(Xi); s}/SC{s|gη(Xi),Xi}]∑n
i=1[Y
∗
i {gη(Xi); s}/SC{s|gη(Xi),Xi}]
)
. (1)
However, since N∗i (gη; s)’s and Y
∗
i (gη; s)’s are generally not observable, Ŝ
∗(u;η) is not
computable based on observed data. To obtain proper estimators that are computable
7
based on observed data, we make the following two assumptions that are widely used in
the causal inference literature (Rubin, 1974): (i) stable unit treatment value assumption
(SUTVA), i.e. T = T ∗(1)A+ T ∗(0)(1− A), and (ii) no unmeasured confounders assump-
tions, i.e. {T ∗(1), T ∗(0)} ⊥⊥ A|X.
2.2 Estimation Procedure
Following Zhang et al. (2012), we cast the estimation of S∗(u;η) in a missing data frame-
work. Specifically, due to SUTVA, for those patients whose actually received treatment
matches with the assigned treatment given by the regime gη, N
∗
i (gη; s) = Ni(s) and
Y ∗i (gη; s) = Yi(s), which are observed. For other patients, they are missing. This moti-
vates us to modify the estimator given in (1) by incorporating inverse propensity score
weighting. Formally, the weight for the ith patient is given by
wηi =
I[Ai = I{ηTX˜ ≥ 0}]
pi(Xi)Ai + {1− pi(Xi)}(1− Ai) =
AiI(η
TX˜ ≥ 0) + (1− Ai){1− I(ηTX˜ ≥ 0)}
pi(Xi)Ai + {1− pi(Xi)}(1− Ai) ,
(2)
where pi(Xi) = P (Ai = 1|Xi) is the propensity score. In practice, pi(Xi) is either known
by design as in randomized clinical trials or needs to be estimated from the data as in
observational studies. For the latter case, a parametric model, say a logistic regression is
usually used for estimating pi(Xi), specifically,
logit{pi(Xi;θ)} = θTX˜i, (3)
where logit(z) = log{z/(1− z)}. Let θˆ denote the maximum likelihood estimator of θ and
define pˆi(Xi) = exp(θˆ
TX˜i)/{1 + exp(θˆTX˜i)}. It is known that if the logistic regression
model is correctly specified, θˆ is a consistent estimator of θ.
To derive the estimator for S∗(u;η), we also need to estimate the censoring time
survival function SC(s|Ai,Xi). In many clinical studies with well follow-up, it is reasonable
to assume that censoring times are independent of treatment assignment and covariates,
i.e. independent censoring assumption. Then, we can use Kaplan-Meier estimator for
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censoring times to consistently estimate SC(s|Ai,Xi). For some applications, independent
censoring assumption may be restrictive. It can be relaxed to a certain extent. For
example, if censoring times are assumed to only depend on treatment assignment, we can
use stratified Kaplan-Meier estimators to estimate the treatment-specific censoring time
survival function. For more general dependence, we can build a semiparametric model, say
a proportional hazards model for censoring times and obtain the model based estimator of
SC(s|Ai,Xi). For simplicity, from now on we make the independent censoring assumption
and let SˆC(·) denote the Kaplan-Meier estimator for censoring times.
Let wˆηi denote the estimator of wηi, which is obtained by replacing pi(Xi) with pˆi(Xi) in
wηi. We propose the following inverse propensity score weighted Kaplan-Meier estimator
(IPSWKME) for S∗(u;η):
ŜI(u;η) =
∏
s≤u
{
1−
∑n
i=1 wˆηidNi(s)∑n
i=1 wˆηiYi(s)
}
. (4)
Note that the IPSWKME actually dose not depend on the Kaplan-Meier estimator SˆC(·)
for censoring times since it is cancelled out from numerator and denominator under the
independent censoring assumption. In Section 4, we will show that ŜI(u;η) is a consistent
estimator of S∗(u;η) under certain conditions. Based on ŜI(u;η), the estimated optimal
treatment regime to maximize t-year survival probability is given by g(x; ηˆoptI ), where
ηˆoptI = arg max||η||=1 ŜI(t;η).
Note that the IPSWKME relies on the correct specification of the propensity score
model. If it is misspecified, the IPSWKME is generally biased. To improve the robustness
of the IPSWKME, we next propose augmented IPSWKME (AIPSWKME) by incorporat-
ing assumed model information. For example, we may posit a proportional hazards (PH)
model (Cox, 1972) for the conditional cumulative hazard function of T by
ΛT (t|A,X) = Λ0(t) exp{βT (XT , A,AXT )T}, (5)
where Λ0(t) is the baseline cumulative hazard function and β is a (2p + 1)-dimentional
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parameter. The augmented term for wηidN
∗
i {gη(Xi); s} is
wηidN
∗
i {gη(Xi); s}+ (1− wηi)E[dN∗i {gη(Xi); s}|Xi]
= wηidN
∗
i {gη(Xi); s}+ (1− wηi)ST (s|gη(Xi),Xi)SC(s)dΛT (s|gη(Xi),Xi),
where ST (s|Ai,Xi) and SC(s) are the conditional survival functions of T and C, respec-
tively. Similarly, the augmented term for wηiY
∗
i {gη(Xi); s} is given by wηiY ∗i {gη(Xi); s}+
(1 − wηi)ST (s|gη(Xi),Xi)SC(s). It can be easily shown that the above two augmented
terms have the so-called doubly robust property, i.e. they are unbiased when either the
propensity score model or the posited PH model is correctly specified. Therefore, we
propose the AIPSWKME for S∗(u;η) as
ŜA(u;η)
=
∏
s≤u
(
1−
∑n
i=1[wˆηidNi(s) + (1− wˆηi)SˆT{s|gη(Xi),Xi}SˆC(s)dΛˆT{s|gη(Xi),Xi}]∑n
i=1[wˆηiYi(s) + (1− wˆηi)SˆT{s|gη(Xi),Xi}SˆC(s)]
)
,
(6)
where SˆT (s|Ai,Xi) is the estimated survival function of T based on the fitted PH model
and SˆC(s) is the Kaplan-Meier estimator for censoring times. Based on ŜA(u;η), the
estimated optimal treatment regime to maximize t-year survival probability is given by
g(x; ηˆoptA ), where ηˆ
opt
A = arg max||η||=1 ŜA(t;η). The asymptotic properties of ŜA(u;η) and
ŜA(t; ηˆ
opt
A ) will be studied in Section 4.
2.3 Computational Aspects
Note that ŜI(t;η) and ŜA(t;η) are not smooth functions of η. In fact, they can be very
wiggly. As an illustration, we plot ŜI(t;η) and ŜA(t;η) as functions of η1 in Figure 2 for a
simple example with one covariate and the intercept of η being set as 1. The black curves
are for the estimates ŜI(t;η) and ŜA(t;η), which are given in the left and right panels
of Figure 2, respectively. It can be clearly seen that the curves are very wiggly, and the
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direct maximization of them with respect to η will be challenging and may lead to local
maximizers. From our simulation studies conducted in Section 5, the estimated survival
probability following the obtained optimal treatment regimes may have substantial biases.
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Figure 2: Plots of original and smoothed value functions.
To reduce the biases of the estimates, we propose to smooth the estimates ŜI(t;η)
and ŜA(t;η) using kernel smoothers. Specifically, we replace the gη(Xi) = I{ηTX˜i ≥ 0}
in ŜI(t;η) and ŜA(t;η) with g˜η(Xi) = Φ
(
ηTX˜i/h
)
to get the smoothed IPSWKME
(S-IPSWKME) S˜I(t;η) and the smoothed AIPSWKME (S-AIPSWKME) S˜A(t;η), where
Φ(s) is the cumulative distribution function for the standard normal distribution and h is a
bandwidth parameter that goes to zero as n goes to infinity. For the bandwidth selection,
we set h = c0n
1/3sd(ηTX˜), where c0 is a constant and sd(v) is the sample standard devia-
tion of v. Such a bandwidth parameter has been widely used in nonparametric smoothing
literature and will ensure that the original estimates and the smoothed estimates have the
same asymptotic distributions. In our numerical studies, we tried different values for c0
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and found that c0 = 4
1/3 generally gives good results for all scenarios. As an illustration,
we plot in Figure 2 the smoothed estimates with the chosen bandwidth parameter for the
same example in red curves. It can be seen that the smoothed curves well approximate
the original curves and have unique maximizers around the true value η1 = 0.5. Let η˜
opt
I
and η˜optA denote the maximizers of S˜I(t;η) and S˜A(t;η), respectively. Then the associated
optimal treatment regimes are g(x; η˜optI ) and g(x; η˜
opt
A ).
3 Estimation of Optimal Treatment Regime for Mul-
tiple Decision Time Points
In this section, we extend our estimation methods to derive optimal dynamic treatment
regimes incorporating multiple decision time points. For the simplicity of presentation, we
use the case with two decision time points as an illustration. Specifically, treatments can
be given at the baseline and an interim time point s, 0 < s < t. For the ith patient, let
X0i denote his or her p0-dimensional vector of baseline covariates and A0i ∈ A0 = {0, 1}
denote the initial treatment received at the baseline. If this patient survives beyond s and
is not censored before s, let X1i denote his or her p1-dimensional vector of intermediate
covariates collected by s after assigning treatment A0i and A1i ∈ A1 = {0, 1} denote
the follow-up treatment given at s. Thus, the observed data are {(X0i, A0i,X1iI{T˜i >
u}), A0iI{T˜i > u}, T˜i, δi), i = 1, . . . , n}.
As for single decision time point, we consider a class of linear dynamic treatment
regimes for simplicity, i.e. G = {gη = (g0, g1)}, where
g0(X0;η0) = I{ηT0 (1,XT0 ) ≥ 0},
g1(X0,X1;η1) = I{ηT1 (1,XT0 , g0(X0;η0),XT1 )) ≥ 0},
and η0 ∈ Rp0+1,η1 ∈ Rp0+p1+2. Here a patient following a treatment regime gη implies that
this patient is given treatment g0(X0;η0) at baseline, and if he or she survives beyond s and
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is not censored before s, this patient will be given treatment g1(X0,X1;η1) at s. Note that
for patients whose initial treatments coincide with those assigned by the regime g0(X0;η0)
and who die before s, their treatment assignments are also consistent with the regime
gη. However, for patients whose initial treatments coincide with those assigned by the
regime g0(X0;η0) but who are censored before s, it is not known whether their treatment
assignments follow the regime gη. Let T
∗(gη(X0,X1)) denote the potential survival time
for a patient if he or she were given treatment regime gη(X0,X1). Here we are interested in
finding the optimal dynamic treatment regime goptη = (g0(X0;η
opt
0 ), g1(X0,X1;η
opt
1 )) in G
that maximizes the t-year survival probability S∗(2)(t;η) = EX0,X1 [P{T ∗(gη(X0,X1)) >
t|X0,X1}]. As commonly used in the causal inference literature for studying dynamic
treatment regimes (e.g., Murphy, 2003), we make two assumptions: (i) SUTVA, i.e. a
patient’s observed outcome agrees with the corresponding potential outcome if his or her
actually received treatments are consistent with the assigned treatments and (ii) sequential
randomization assumption (SRA), i.e. the treatment assignment at current stage only
depends on the past received treatments and observed covariates, but not the potential
outcomes. Under these two assumptions, the above defined t-year survival probability can
be estimated from observed data.
Next, we propose a similar inverse propensity score weighted Kaplan-Meier estimator
for the survival function S∗(2)(u;η) given any treatment regime gη. However, the derivation
of proper weights becomes more difficult since some patients may be censored before s and
whether their received treatments follow the regime gη is unknown. To take this into
account, we define the following new weight for patient i, i = 1, . . . , n:
wˆ
(2)
ηi =
I(T˜i ≤ s)× δi
SˆC(T˜i)
× I{A0i = g0(X0i;η0)}
pˆiA0(X0i)
+
I(T˜i > s)
SˆC(s)
× I{A0i = g0(X0i;η0), A1i = g1(X0i, g0(X0i;η0), X1i;η1)}
pˆiA0(X0i)× pˆiA1(X0i,X1i)
,
where pˆiA0(X0i) = pˆi0(X0i)A0i+{1− pˆi0(X0i)}(1−A0i), pˆiA1(X0i,X1i) = pˆi1(X0i,X1i)A1i+
{1− pˆi1(X0i,X1i)}(1−A1i), and pˆi0(X0i) and pˆi1(X0i,X1i) are the estimates of the propen-
sity scores P (A0i = 1|X0i) and P (A1i = 1|X0i,X1i), respectively. In randomized studies,
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pˆi0 and pˆi1 are known by design, while in observational studies, they need to be estimated
from day, say using logistic regression. Then the new IPSWKME for S∗(u;η) is given by
Ŝ
(2)
I (u;η) =
∏
v≤u
{
1−
∑n
i=1 wˆ
(2)
ηi dNi(v)∑n
i=1 wˆ
(2)
ηi Yi(v)
}
. (7)
Let ηˆ
opt,(2)
I = (ηˆ
opt,(2)
I,0 , ηˆ
opt,(2)
I,1 ) = arg max||η0||=1,||η1||=1 Ŝ
(2)
I (t;η). Then the estimated opti-
mal dynamic treatment regime is given by gˆ
opt,(2)
η = (g0(X0; ηˆ
opt,(2)
I,0 ), g1(X0,X1; ηˆ
opt,(2)
I,1 )).
To improve the finite sample performance of the IPSWKME, we also introduce kernel
smoothing here. Specifically, we replace the indicator functions g0(X0i;η0) and g1(X0i,X1i;η1)
in Ŝ
(2)
I (u;η) with Φ
(
ηT0 (1,X
T
0i)/h0
)
and Φ
(
ηT1 (1,X
T
0 , g0(X0;η0),X
T
1 ))/h1
)
, where the
bandwidth parameters h0 and h1 are chosen similarly as before. Let S˜
(2)
I (u;η) denote the
resulting smoothed IPSWKME and η˜
opt,(2)
I denote the maximizer of S˜
(2)
I (t;η). To improve
the robustness of IPSWKME, we can similarly derive the augmented IPSWKME based
on a posited model for survival time, however, its formulation will be very complicated
and is not pursued here. In addition, conceptually, the proposed IPSWKME can be gen-
eralized to accommodate more than two decision time points. However, when there are
more treatment decision time points, the IPSWKME may become less reliable since fewer
patients will follow a given dynamic treatment regime.
4 Asymptotic Properties
In this Section, we present the asymptotic properties of the proposed estimators which are
summarized in Theorems 1 - 3.
Theorem 1. Under conditions (A1)-(A6) in the Appendix, if the propensity score model (3)
is correctly specified, for any regime gη, we have, as n→∞,
(i.) ŜI(u;η)→p S∗(u;η) for any 0 < u ≤ t;
(ii.)
√
n{ŜI(u;η)− S∗(u;η)} converges weakly to a mean zero Gaussian process;
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(iii.)
√
n{ŜI(t; ηˆoptI )−S∗(t;ηopt)} →d N(0,ΣI(t;ηopt)), where the expression of ΣI(t;ηopt)
is given in the Appendix;
(iv.)
√
n{ŜI(t; ηˆoptI )− S˜I(t; η˜optI )} = op(1).
Theorem 2. Under condition (A1)-(A6) in the Appendix, if either the propensity score
model (3) or the proportional hazard model (5) is correctly specified, we have, as n→∞,
(i.) ŜA(u;η)→p S∗(u;η) for any 0 < u ≤ t;
(ii.)
√
n{ŜA(u;η)− S∗(u;η)} converges weakly to a mean zero Gaussian process;
(iii.)
√
n{ŜA(t; ηˆoptA )−S∗(t;ηopt)} →d N(0,ΣA(t;ηopt)), where the expression of ΣA(t;ηopt)
is given in the Appendix;
(iv.)
√
n{ŜA(t; ηˆoptA )− S˜A(t; η˜optA )} = op(1).
Theorem 3. Under certain regularity conditions, if the two propensity score models pi0(·)
and pi1(·) are correctly specified, for any regime gη, we have, as n→∞,
(i.) Ŝ
(2)
I (u;η)→p S∗(2)(u;η) for any 0 < u ≤ t;
(ii.)
√
n{Ŝ(2)I (u;η)− S∗(2)(u;η)} converges weakly to a mean zero Gaussian process;
(iii.)
√
n{Ŝ(2)I (t; ηˆopt,(2)I )−S∗(t;ηopt,(2))} →d N(0,Σ(2)I (t;ηopt,(2))), where ηopt,(2) = (ηopt0 ,ηopt1 );
(iv.)
√
n{Ŝ(2)I (t; ηˆopt,(2)I )− S˜(2)I (t; η˜opt,(2)I )} = op(1).
Here the asymptotic variance ΣI(t;η
opt), ΣA(t;η
opt) and Σ
(2)
I (t;η
opt,(2)) can be con-
sistently estimated from observed data using the usual plug-in method. The proofs of
Theorems 1-3 are given in the Appendix.
5 Simulation Studies
In this Section, we examine the finite sample performance of the proposed estimators by
simulations. We first consider scenarios with a single treatment decision time point at
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the baseline. For each patient, the baseline covariates X1 and X2 are independently and
uniformly distributed on (−2, 2). Given the covariates X1 and X2, the binary treatment
indicator A is generated from the logistic model logit{pi(X1, X2)} = X1 − 0.5X2. The
survival time T is generated from a linear transformation model (Cheng et al., 1995),
h(T ) = −0.5X1 + A(X1 −X2) + ε, where h(s) = log(es − 1)− 2 is an increasing function
and the error term ε follows some known distribution, taking either the extreme value
distribution or the logistic distribution, which corresponds to a proportional hazards and
proportional odds model, respectively. The covariate-independent censoring time C is uni-
formly distributed on (0, C0), where C0 is chosen to achieve the censoring rate of 15% and
40%. It is obvious the optimal treatment regime for maximizing t-year survival probability
is goptη (X1, X2) = I{X1−X2 ≥ 0} for any t. Here, we search the optimal treatment regime
in the class of regimes given by G = {gη : gη(X1, X2) = I{η0 +η1X1 +η2X2 ≥ 0},η ∈ R3},
which contains the true optimal treatment regime as a special case. For easy comparion,
we impose the restriction ηTη = 1 and thus we have ηopt = (0, 0.707,−0.707).
To implement our proposed estimators, we need to posit a model for the propen-
sity scores. Here, we consider both a correctly specified model: logit{pi(X1, X2)} =
θ0 + θ1X1 + θ2X2 and a misspecified model: logit{piA(X1, X2)} = θ0. For the augmented
estimators, we need to posit a model for the survival time T . Here, we always use the pro-
portional hazard model λ(t|X1, X2) = λ0(t) exp{β11X1 +β12X2 +A(β20 +β21X1 +β22X2)}.
Note that when ε follows the extreme value distribution, the posited survival model is
correctly specified. On the other hand, when ε follows the logistic distribution, this model
is misspecified. We compared the performance of the IPSWKME (SˆI) and AIPSWKME
(SˆA), as well as their smoothed versions: S-IPSWKME (S˜I) and S-AIPSWKME (S˜A),
under different combinations of the assumed propensity score (PS) model, error term dis-
tribution, censoring rate, sample size (n = 250 or 500) and time point of interest (t = 1
or 2). For each scenario, we run 1000 replications and use the genetic algorithm to do the
optimization, which is implemented by the R function genoud within the package rgenoud
(Mebane, Jr. and Sekhon, 2011).
To save the presentation space, we only report the simulation results for the scenarios
with n = 250 and t = 2, which are given in Tables 1 and 2 for the extreme value error and
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logistic error distributions, respectively. Results for other scenarios are very similar and
omitted here. In the tables, we report the mean of estimated η, the mean of estimated
t-year survival probability following the estimated optimal treatment regime, namely the
estimated optimal t-year survival probability (denoted by Sˆ(ηˆopt)), the mean of estimated
standard error of Sˆ(ηˆopt) using the plug-in method based on the asymptotic variances
established in Theorems 1-2 (denoted by SE), the empirical coverage probability of 95%
confidence interval for the t-year survival probability following the true optimal treatment
regime S(ηopt) (denoted by CP), the mean of simulated true t-year survival probability
following the estimated optimal treatment regime (denoted by S(ηˆopt)), and the mean
of misclassification rate by comparing the true and estimated optimal treatment regimes
(denoted by MR). The numbers given in parenthesis are the standard deviation of the
corresponding estimates. Here, S(ηopt) and S(ηˆopt) are computed using simulated survival
times following the given treatment regime based on a large random sample of 5 × 106
patients. We have S(ηopt) = 0.605 for the extreme value error distribution and S(ηopt) =
0.672 for the logistic distribution. In addition, the misclassification rate for one simulation
is calculated as the proportion of patients that the true and estimated optimal treatment
regimes do not match.
From the results, we make the following observations. First, when the PS model is
correctly specified, all the estimators of ηopt have relatively small biases, in particular, the
mean of ηˆopt0 is close to zero while the mean ratio of ηˆ
opt
1 to ηˆ
opt
2 is very close to nega-
tive one. The means of simulated true t-year survival probability following the estimated
optimal treatment regimes, i.e. S(ηˆopt), are all close to the true values. In addition,
the estimates of ηopt based on the AIPSWKME and S-AIPSWKME of t-year survival
probability generally have smaller standard deviation than those based on IPSWKME
and S-IPSWKME. Second, the unsmoothed IPSWKME and AIPSWKME of the optimal
t-year survival probability have relatively large biases mainly due to the very wiggly es-
timates of t-year survival probability as illustrated in Figure 2 and as a consequence, the
associated coverage probability of 95% confidence interval is much lower than the nominal
level. Third, the smoothed S-IPSWKME and S-AIPSWKME of the optimal t-year survival
probability greatly reduce the biases and thus give the proper coverage probability. In ad-
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dition, the unsmoothed and smoothed estimators of the optimal t-year survival probability
have nearly the same standard deviation. Fourth, when the PS model is misspecified, the
IPSWKME and S-IPSWKME generally have relatively large biases as expected, while the
AIPSWKME and S-AIPSWKME greatly reduce the biases and give much smaller MR. In
particular, when the posited survival model is correctly specified under the extreme value
error distribution, the S-AIPSWKME gives proper coverage probability. On the other
hand, when the posited survival model is misspecified under the logistic error distribu-
tion, although the S-AIPSWKME is not consistent in general, it still gives small biases
with reasonable coverage probability. Lastly, the performance of our proposed estimators
improve as the censoring rate decreases and sample size increases.
Next, we consider scenarios with two treatment decision time points, one at the baseline
and the other at s = 1. The initial treatment assignment A0 and the follow-up treatment
assignment A1, if applicable, are generated independently from a Bernoulli distribution
with success probability of 0.5. A single baseline covariate is generated from a uniform
distribution on (0, 4). To generate the survival time T , we first generate a time T1 given A0
and X0 from an exponential distribution with the rate function λ1(A0, X0). The censoring
time C is generated from a uniform distribution on (0, C0). If a patient is neither dead
nor censored at time s = 1 (i.e. min(T1, C) > 1), we generate a single intermediate
covariate X1 for this patient by X1 = 0.5X0 − 0.4(A0 − 0.5) + e, where e is uniformly
distributed on (0, 2). Then we generate another time T2 given A0, A1, X0 and X1 from
an exponential distribution with the rate function λ2(A0, A1, X0, X1). The survival time
T of interest is defined as T = T1 if T1 ≤ 1 and T = 1 + T2 otherwise. The observed
survival time is T˜ = min(T,C) with the censoring indicator δ = I(T ≤ C). Here the
constant C0 is chosen to achieve the censoring rate of 15% and 40%. We consider three
scenarios for the rate functions λ1 and λ2: (i) λ1(A0, X0) = 0.5 exp{1.75(A0−0.5)(X0−2)}
and λ2(A0, A1, X0, X1) = 0.3 exp{2.5(A1 − 0.4)(X1 − 2) − A0(X1 − 2)}; (ii) λ1(A0, X0) =
0.1 exp{2(A0−0.5)(X0−2)} and λ2(A0, A1, X0, X1) = 0.2 exp{3(A1−0.4)(X1−2)−3(A0−
0.5)(X0 − 2)}; (iii) λ1(A0, X0) = 0.2 exp{1.5(A0 − 0.3)(X0 − 3)} and λ2(A0, A1, X0, X1) =
0.3 exp{2(A1 − 0.5)(X1 − 2) + 0.5(A0 − 0.7)(X0 − 1)}.
For the above three scenarios, it is easy to see that the true optimal treatment regime
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for maximizing t-year survival probability (t > 1) at time s = 1 is given by gopt1 =
I(2 −X1 > 0). However, the true optimal treatment regime gopt0 at time s = 0 is a very
complicated nonlinear function of X0, which can be derived using backward induction as
done in Q-learning. In our implementation, for computation simplicity, we search the
optimal dynamic treatment regime in a class of linear decision rules, specifically, Gη =
{g0(X0) = I{η1 + η2X0 > 0}, g1(X1) = I{η3 + η4X1 > 0}, ||(η1, η2)|| = 1, ||(η3, η4)|| = 1}.
It is clear that the true optimal treatment regime at s = 1 is contained in the class but
the true optimal treatment regime at s = 0 is not. For scenarios (i) and (iii), we take
t = 3, while for (ii) we take t = 6. Instead of finding the true optimal treatment regime
at s = 0, we use simulation method to find the best treatment regime at s = 0 in the
class Gη to maximize t-year survival probability. To be specific, we first generate X0, and
for a given (η1, η2), we set A0 by the regime g0(X0). Then, we generate X1 given A0
and X0 the same way as in our design, and set A1 by the optimal regime g
opt
1 . Finally,
we generate T1 and T2, and define T the same way as before. Based on the generated
T ’s for a large random sample of 5 × 106 patients, we compute the associated empirical
t-year survival probability. We find (ηopt1 , η
opt
2 ) to maximize the empirical t-year survival
probability, which gives the best treatment regime gopt0 in the class Gη. Here we use
grid search method to find (ηopt1 , η
opt
2 ). Since ||(ηopt1 , ηopt2 )|| = 1, we only need to do grid
search for η1. We have (η
opt
1 , η
opt
2 ) = (0.890,−0.456) and S(3;ηopt) = 0.567 for scenario
1, (ηopt1 , η
opt
2 ) = (−0.891, 0.454) and S(6;ηopt) = 0.624 for scenario 2, and (ηopt1 , ηopt2 ) =
(0.908,−0.419) and S(3;ηopt) = 0.702 for scenario 3. Here ηopt = (ηopt1 , ηopt2 , ηopt3 , ηopt4 ) and
S(t;ηopt) is the t-year survival probability following the optimal dynamic treatment regime
ηopt. Note that (ηopt3 , η
opt
4 ) = (0.894,−0.447) after normalization for all three scenarios.
We compare the unsmoothed and smoothed estimators. For both estimators, the
propensity score models pi0 and pi1 are assumed known as for randomized clinical tri-
als. Simulation results are summarized in Table 3. From the results, we observe: (i)
both unsmoothed and smoothed estimation methods give nearly unbiased estimators of
ηopt, and the t-year survival probability following the estimated optimal treatment regime
(denoted by S(ηˆopt) in the table) is very close to the t-year survival probability following
the true optimal treatment regime ηopt; (ii) the mean of estimated standard error (SE) of
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Sˆ(ηˆopt) based on the established theory is close to the standard deviation of the estimates
given in the parenthesis; (iii) The unsmoothed estimator for the t-year survival probabil-
ity following the estimated optimal treatment regime (denoted by Sˆ(ηˆopt)) has relatively
large bias and the associated coverage probability (CP) is below the nominal level; and (iv)
the smoothed estimator for the t-year survival probability following the estimated optimal
treatment regime has largely reduced bias and thus lead to proper coverage probability.
6 A Data Example
We illustrate the proposed methods with the data from the AIDS Clinical Trials Group
Study 175 (Hammer et al., 1996). This is a randomized clinical trial and patients were
randomized to four treatment groups with equal probability: zidovudine (ZDV) monother-
apy, ZDV plus didanosine (ddI), ZDV plus zalcitabine (zal), and ddI monotherapy. A
primary endpoint of interest is the time to having a larger than 50% decline in the CD4
count, or progressing to AIDS, or death, whichever comes first. From treatment-specific
Kaplan-Meier curves, it can be clearly seen that treatments ZDV+ddI, ZDV+zal and ddI
only are uniformly better than treatment ZDV only in terms of survival. In addition,
treatments ZDV+ddI and ZDV+zal are overall the two best treatments giving the high-
est survival probabilities especially after day 400. For simplicity, we only consider two
treatment options in our analysis , specifically, A = 1 for zidovudine+ddI and A = 0
for zidovudine+zal, which involves 1046 patients. For each patient, there are 12 base-
line clinical covariates. From historical studies (e.g., Geng et al., 2014), it is found that
Karnofsky score (Karnof), baseline CD4 count (CD40), and age (Age) are three impor-
tant risk predictors and may have interaction effects with treatments. In our analysis,
we only include these three covariates in constructing treatment regimes. Our goal is
to find the optimal treatment regime TO from the class of linear regimes defined by
G = {gη = I(η0 + η1Karnof + η2CD40 + η3Age ≥ 0) : η ∈ R4} to maximize t-year survival
probability. To simplify notation, we define X1 as Karnof, X2 as CD40 and X3 as Age.
Since the data comes from a randomized study, we use a constant model for the propen-
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sity score and estimate this constant from data. For the augmented estimation, we posit
the proportional hazard model as given in (5). We consider t = 400, 600, 800 and 1000.
We only compute the S-IPSWKME and S-AIPSWKME, since they have better numerical
performance than their nonsmoothed counterparts based on our simulation studies.
The estimated optimal treatment regimes and the associated t-year survival probabil-
ities are presented in Table 4. The numbers given in the columns of Intercept, Karnof,
CD40 and Age are the parameter estimates η˜opt defining the optimal treatment regimes,
and S˜(t; η˜opt) is the estimated t-year survival probability following the estimated optimal
treatment regime. We make the following observations: (i) the estimated optimal treat-
ment regime at earlier time may be different from that at later time. For example, com-
paring the obtained optimal treatment regimes at t = 600 and t = 800, the S-IPSWKME
assigns a set of 355 patients to treatment 0 and another set of 585 patients to treatment
1 at both time points. However, it assigns a set of 51 patients to treatment 0 at day 600
but to treatment 1 at day 800. On the other hand, it assigns another set of 55 patients
to treatment 1 at day 600 but to treatment 0 at day 800. For the S-AIPSWKME, the
findings are similar. (ii) The S-IPSWKME and S-AIPSWKME may give very different
parameter estimates η˜opt. However, the corresponding optimal treatment regimes may
be similar. Using the results at day 600 as an example, among the 1046 patients, there
are only 68 patients whose assigned treatments are different by the estimated optimal
treatment regimes based on S-IPSWKME and S-AIPSWKME. In addition, the estimated
t-year survival probabilities following the estimated optimal treatment regimes are nearly
the same based on S-IPSWKME and S-AIPSWKME.
Next, we compare the estimated optimal regimes with the simple regimes that assign
everyone to the same treatment. Specifically, we construct the 95% confidence intervals
for the difference between the estimated t-year survival probabilities under the estimated
optimal treatment regimes and the simple regimes using two methods: one is the Wald-
type confidence interval based on the derived asymptotic normal distribution and the other
is the bootstrap confidence interval based on 500 runs. The results are given in Table 5.
From the results we observe that (i) the Wald-type confidence interval and bootstrap
confidence interval are very similar; (ii) the bootstrap confidence intervals all stay above
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0 when comparing the estimated t-year survival probabilities under the estimated optimal
treatment regimes and the simple regimes for all the considered time points, indicating that
the estimated optimal treatment regimes significantly improves t-year survival probabilities
comparing with simple regimes; (iii) Some Wald-type confidence interval based on normal
approximation stays above 0 and others contain 0. However, for those that contain 0, zero
is very close to the left end of the intervals. Therefore, similar conclusions can be made
here as for the bootstrap confidence intervals, although they are a little less significant.
7 Discussion
In this paper, we propose various Kaplan-Meier type estimators for the survival function
of patients following a given (dynamic) treatment regime. We further introduce kernel
smoothing for the proposed estimators to improve their numerical performance. Then, the
optimal (dynamic) treatment regime is searched within a class of pre-specified treatment
regimes to maximize the associated t-year survival probability. Current work only considers
the case when there are two treatment options at each decision time point. However, the
proposed method can be generalized to incorporate multiple treatment options at each
decision time point by defining a treatment regime using multiple indexes instead of a
single indicator function gη(X) = I{ηTX˜ ≥ 0}. In addition, current methods find the
optimal (dynamic) treatment regime to maximize t-year survival probability, which can
also be generalized to maximize other clinical outcomes of interest. Specifically, using
the IPSWKME, ŜI(·;η), as an illustration, we can find the optimal treatment regime to
maximize f{ŜI(·;η)}, where f is a specified function of interest. For example, if we take
f{ŜI(·;η)} =
∫ L
0
ŜI(u;η)du, which corresponds to the restricted mean survival time under
a given treatment regime. On the other hand, if we take f{ŜI(·;η)} = sup{u : ŜI(u;η) ≥
0.5} , which corresponds to the median survival time under a given treatment regime.
These are interesting topics that need further investigation.
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A Proof of Theorems
To establish the asymptotic results given in Theorems 1-2, we need to assume some regu-
larity conditions. Recall that a working logistic model (3) is assumed for the propensity
scores with parameters θ for the IPSWKME and a working proportional hazards model
(5) is further assumed for the survival time T for the AIPSWKME with parameters β and
Λ0. Let νAi = (X
T
i , Ai, AiX
T
i )
T and νηi = (X
T
i , gη(Xi), gη(Xi)X
T
i )
T . Define
KI1 (X, A, T˜ , δ;η) =
∫ t
0
(2A− 1)dN(u)
pi∗E{w∗ηY (u)}
,
KI2 (X, A, T˜ , δ;η) =
∫ t
0
(2A− 1)Y (u)E[{(2A− 1)gη(X) + (1− A)}dN(u)]
[pi∗E{w∗ηY (u)}]2
,
where w∗η = [Agη(X)+(1−A){1−gη(X)}]/pi∗ and pi∗ = pi(X;θ∗)A+{1−pi(X;θ∗)}(1−A).
In addition, define
KA1 (X, A, T˜ , δ;η) =
∫ t
0
JA1 (u)− JA0 (u)
E [{LA1 (u)− LA0 (u)}gη(X) + LA0 (u)]
,
KA2 (X, A, T˜ , δ;η) =
∫ t
0
{LA1 (u)− LA0 (u)}E
[{JA1 (u)− JA0 (u)}gη(X) + JA0 (u)]
(E [{LA1 (u)− LA0 (u)} gη(X) + LA0 (u)])2
,
where JAk (u) =
1−k−(−1)kA
pi∗ dN(u)+ek
(
1− 1−k−(−1)kA
pi∗
)
exp {−Λ∗0(u)ek}SC(u)dΛ∗0(u), LAk (u) =
1−k−(−1)kA
pi∗ Y (u)+
(
1− 1−k−(−1)kA
pi∗
)
exp {−Λ∗0(u)ek}SC(u), ek = exp
{
β∗T (XT , k, kXT )T
}
,
k = 0, 1. We assume the following conditions.
A1. The covariates X are bounded.
A2. The propensity score pi(X) is bounded away from 0 and 1 for all possible values of
X.
A3. The equation E
[{
A− exp(θT X˜)
1+exp(θT X˜)
}
X˜
]
= 0 has a unique solution θ∗.
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A4. The equation
E
(∫ τ
0
[
νAi −
E
{
Yi(s) exp(β
TνAi)νAi
}
E {Yi(s) exp(βTνAi)}
]
× dNi(s)
)
= 0.
has a unique solution β∗, where τ > t is a pre-specified time point satisfying P (T˜i ≥
τ) > 0. Let Λ∗0(u) = E[
∫ u
0
dNi(s)/E{Yi(s) exp(β∗TνAi)}] and it satisfies Λ∗0(τ) <∞.
A5. sup||η||=1E[{KIj (X, A, T˜ , δ;η)}2] < ∞ and sup||η||=1E[{KAj (X, A, T˜ , δ;η)}2] < ∞,
j = 1, 2.
A6. nh→∞ and nh4 → 0 as n→∞.
Under assumed regularity conditions A1 - A4, we have the following asymptotic rep-
resentations:
√
n(θˆ − θ∗) = 1√
n
n∑
i=1
φ1i + op(1),
√
n(βˆ − β∗) = 1√
n
n∑
i=1
φ2i + op(1),
√
n{Λˆ0(u)−Λ∗0(u)} =
1√
n
n∑
i=1
φ3i(u)+op(1),
√
n{SˆC(u)−SC(u)} = 1√
n
n∑
i=1
φ4i(u)+op(1),
where φ1i’s and φ2i’s are independently and identically distributed mean-zero vectors, and
φ3i(u) and φ4i(u) are independent mean-zero processes.
A.1 Proof of Theorem 1
For any given regime gη, we first derive the asymptotic properties for the corresponding
inverse propensity score weighted (IPSW) Nelson-Aalen estimator. Specifically,
Λ̂I(u;η) ≡ Λ̂I(u;η, θˆ) =
∫ u
0
∑n
i=1 wˆηidNi(s)∑n
i=1 wˆηiYi(s)
. (A.1)
It is easy to show that ŜI(u;η) and exp{−Λ̂I(u;η)} are asymptotically equivalent for any
given η. Therefore, the asymptotic properties of ŜI(u;η) easily follows those of Λ̂I(u;η).
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When the propensity score model is correctly specified, we have that θ∗ = θ and w∗ηi =
wηi. Then n
−1∑n
i=1 wˆηiYi(s) →p E{wηiYi(s)} = E[Y ∗{gη(X); s}] uniformly for s ∈ [0, τ ]
as n→∞. Similarly, we have n−1∑ni=1 wˆηidNi(s)→p E{wηidNi(s)} = E[dN∗{gη(X); s}]
uniformly for s ∈ [0, τ ] as n→∞. Therefore,
Λ̂I(u;η)→p
∫ u
0
E[dN∗{gη(X); s}]
E[Y ∗{gη(X); s}] =
∫ u
0
SC(s)dP [T
∗{gη(X)} ≤ s]
SC(s)P [T ∗{gη(X)} ≥ s]
= − log{S∗(u;η)} ≡ Λ∗(u;η),
which establish the consistency given in (i) of Theorem 1.
Next, we derive the asymptotic distribution of Λ̂I(u;η). By applying the first-order
Taylor expansion of Λ̂I(u;η) with respect to parameter θ, we have
√
n{Λ̂I(u;η)− Λ∗(u;η)} =
√
n{Λ̂I(u;η,θ)− Λ∗(u;η)}+D1(u)T
√
n(θˆ − θ) + op(1),
where D1(u) = limn→∞ ∂Λ̂I(u;η,θ)/∂θ. In addition,
√
n{Λ̂I(u;η,θ)− Λ∗(u;η)} =
√
n
∫ u
0
∑n
i=1wηi{dNi(s)− Yi(s)dΛ∗(s;η)}∑n
i=1wηiYi(s)
= n−1/2
n∑
i=1
∫ u
0
wηi[dN
∗
i {gη(X); s} − Y ∗i {gη(X); s}dΛ∗(s;η)]
E[Y ∗{gη(X); s}] + op(1)
= n−1/2
n∑
i=1
∫ u
0
wηidM
∗
i {gη(X); s}
E[Y ∗{gη(X); s}] + op(1),
where M∗i {gη(X); s} = N∗i {gη(X); s} −
∫ s
0
Y ∗i {gη(X); v}dΛ∗(v;η) is a mean-zero martin-
gale process. Therefore,
√
n{Λ̂I(u;η)− Λ∗(u;η)} = n−1/2
n∑
i=1
(∫ u
0
wηidM
∗
i {gη(X); s}
E[Y ∗{gη(X); s}] +D1(u)
Tφ1i
)
+ op(1)
≡ n−1/2
n∑
i=1
ζi(u;η) + op(1),
where ζi(u;η)’s are independent mean-zero processes. By delta method, we have
√
n{ŜI(u;η)−
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S∗(u;η)} = −S∗(u;η)n−1/2∑ni=1 ζi(u;η) + op(1), which converges weakly to a mean-zero
Gaussian process by applying the empirical process theory. This proves (ii) of Theorem 1.
Since ηˆoptI is the maximizer of ŜI(t;η) and η
opt is the maximizer of S∗(t;η), following
the similar arguments in Zhang et al. (2012), we have
√
n{ŜI(t; ηˆoptI )− S∗(t;ηopt)} −
√
n{ŜI(t;ηopt)− S∗(t;ηopt)} = op(1).
It follows that
√
n{ŜI(t; ηˆoptI ) − S∗(t;ηopt)} →d N(0,ΣI(t;ηopt)), where ΣI(t;ηopt) =
{S∗(u;ηopt)}2E{ζ2i (u;ηopt)}. This proves (iii) of Theorem 1.
Finally, we show that ŜI(t; ηˆ
opt
I ) and S˜I(t; η˜
opt
I ) are asymptotically equivalent. For any
given η, we have
√
n
{
Λ˜I(t;η)− Λ̂I(t;η)
}
=
√
n× 1
n
n∑
i=1
{
Φ
(
ηTXi
h
)
− I (ηTXi ≥ 0)}×KI1 (Xi, Ai, T˜i, δ;η) (A.2)
+
√
n× 1
n
n∑
i=1
{
Φ
(
ηTXi
h
)
− I (ηTXi ≥ 0)}×KI2 (Xi, Ai, T˜i, δ;η) (A.3)
+ op(1),
For simplicity, define q = (Xi, Ai, T˜i, δ) and r
η = ηTX . Following the similar arguments
in Heller (2007), we have
|(A.2)| ≤M√n sup||η||=1
∣∣∣∣∫
q
∫
rη
{
Φ
(
rη
h
)
− I(rη ≥ 0)
}
KI1 (q;η)dFˆ (r
η|q;η)dGˆ(q;η)
∣∣∣∣ ,
where M is a finite constant, Gˆ(q;η) and Fˆ (rη|q;η) are the marginal empirical cumu-
lative distribution functions for q and the conditional empirical cumulative distribution
function for rη, respectively. For simplicity, we omit the superscript η in rη, the con-
dition η in KI1 (q;η), Fˆ (r|q;η) and Gˆ(q;η). Thus, the equation (A.2) is bounded by
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M
√
n sup||η||=1 |Υ|, where
Υ =
∫
q
∫
r
{
Φ
( r
h
)
− I(r ≥ 0)
}
KI1 (q)dFˆ (r|q)dGˆ(q).
Write Υ = Υ1 + Υ2, where
Υ1 =
∫
q
∫
r
{
Φ
( r
h
)
− I(r ≥ 0)
}
KI1 (q)
{
dFˆ (r|q)− dF (r|q)
}
dGˆ(q)
Υ2 =
∫
q
∫
r
{
Φ
( r
h
)
− I(r ≥ 0)
}
KI1 (q)dF (r|q)dGˆ(q)
with F (r|q) = limn→+∞ Fˆ (r|q). By variable transformation z = r/h and integration by
parts, we have
Υ1 =
∫
q
∫
z
KI1 (q)ϕ(z)
{[
Fˆ (zh|q)− F (zh|q)
]
−
[
Fˆ (0|q)− F (0|q))
]}
dzdGˆ(q), (A.4)
where ϕ(z) is the probability density function of standard normal distribution. Under
regularity condition A5, we apply the results on oscillations of empirical process (Shorack
and Wellner, 2009) to equation (A.4) and have
√
n|Υ1| = Op
(√
h log n log
(
1
h log n
))
.
In addition, by similar arguments and applying second order Taylor expansion of Υ2 with
respect to h around 0, we have
Υ2 = −h
2
2
∫
q
∫
z
KI1 (q)ϕ(z)f
′(zh∗|q)z2dzdGˆ(q),
where f ′(u|q) = ∂2F (u|q)/∂u2 and h∗ lies between h and 0. Thus, we have √n|Υ2| =
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Op(
√
nh2). Combine the above results, we have
|(A.2)| ≤ √n|Υ1|+
√
n|Υ2| = Op
(√
h log n log
(
1
h log n
)
+
√
nh2
)
.
By condition A6, we have sup||η||=1 |(A.2)| = op(1). Similarly, we have sup||η||=1 |(A.3)| =
op(1). Therefore, we have
√
n{Λ˜I(t;η) − Λ̂I(t;η)} = op(1) uniformly in η, which implies
√
n{S˜I(t;η) − ŜI(t;η)} = op(1) uniformly in η. In addition, it is easy to show that
√
n{S˜I(t; η˜optI )− S˜I(t;ηopt)} = op(1) and
√
n{ŜI(t; ηˆoptI )− ŜI(t;ηopt)} = op(1). It follows
that
√
n{S˜I(t; η˜optI )− ŜI(t; ηˆoptI )} = op(1), which proves (iv) of Theorem 1.
A.2 Proof of Theorem 2
For any given regime gη, we similarly introduce the augmented IPSW Nelson-Aalen esti-
mator
Λ̂A(u;η) =
∫ u
0
∑n
i=1 wˆηidNi(s) + (1− wˆηi)SˆT (s|gη(Xi),Xi)SˆC(s)dΛˆT (s|gη(Xi),Xi)∑n
i=1 wˆηiYi(s) + (1− wˆηi)SˆT (s|gη(Xi),Xi)SˆC(s)
.
(A.5)
We will show that Λ̂A(u;η) is consistent when either the propensity score model is correctly
specified or the survival model for T is correctly specified, i.e. having the doubly robustness
property. First, assume that the propensity score model is correctly specified. Then, we
have θ∗ = θ and w∗ηi = wηi. In addition, the denominator of equation (A.5) converges
in probability to E{wηiYi(s)}+E
[
(1− wηi) exp{−Λ∗0(s) exp(β∗Tνηi)}SC(s)
]
uniformly for
s ∈ [0, τ ]. Note that the second term is zero since E(wηi|Xi) = 0. Similarly, the numerator
of equation (A.5) converges in probability to
E{wηidNi(u)}+ E
[
(1− wηi) exp{−Λ∗0(u) exp(β∗Tνηi)}SC(u) exp(β∗Tνηi)dΛ∗0(u)
]
uniformly for s ∈ [0, τ ], where the second term is also zero. The proof of consistency then
follows that for the IPSW Nelson-Aalen estimator.
On the other hand, when the survival model for T is correctly specified, we have β∗ = β
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and Λ∗0(s) = Λ0(s). We can show that the denominator of equation (A.5) converges in
probability to
E
[
exp{−Λ0(s) exp(βTνηi)}SC(s)
]
+ E
(
w∗ηi[Yi(s)− exp{−Λ0(s) exp(βTνηi)}SC(s)]
)
uniformly for s ∈ [0, τ ], where the first term equals to S∗(s;η)SC(s) and the second term is
zero since E[Yi(s)−exp{−Λ0(s) exp(βTνηi)}SC(s)|Ai,Xi] = 0. In addition, the numerator
of equation (A.5) converges in probability to
E
[
exp{−Λ0(s) exp(βTνηi)}SC(s) exp(βTνηi)dΛ0(s)
]
+E
(
w∗ηi[dNi(u)− exp{−Λ0(s) exp(βTνgi)}SC(s) exp(βTνηi)dΛ0(u)]
)
uniformly for s ∈ [0, τ ], where the first term equals to −SC(s)dS∗(s;η) and the second
term is zero since E[dNi(u)−exp{−Λ0(s) exp(βTνgi)}SC(s) exp(βTνηi)dΛ0(u)|Ai,Xi] = 0.
Therefore, the remaining proof follows that for the IPSW Nelson-Aalen estimator.
Next, we derive the asymptotic distribution for ŜA(u;η), assuming that either the
propensity score model or the survival model for T is correctly specified. Note that
Λ̂A(u;η) = Λ̂A(u;η, θˆ, βˆ, Λˆ0, SˆC). By Taylor expansion of Λ̂A(u;η, θˆ, βˆ, Λˆ0, SˆC) with re-
spect to the estimators θˆ, βˆ, Λˆ0 and SˆC around their population values, we have
√
n{Λ̂A(u;η)−Λ∗(u;η)} =
√
n{Λ̂A(u;η,θ∗,β∗,Λ∗0, SC)−Λ∗(u;η)}+n−1/2
n∑
i=1
ψ2i(u;η)+op(1),
where ψ2(u;η)’s are independent mean-zero processes due to the asymptotic expansions
of the estimators θˆ, βˆ, Λˆ0 and SˆC . By simple algebra, we have
√
n{Λ̂A(u;η,θ∗,β∗,Λ∗0, SC)− Λ∗(u;η)} = n−1/2
n∑
i=1
∫ u
0
dhi(s)
E[Y ∗{gη(X); s}] + op(1),
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where
dhi(s) =w
∗
ηi{dNi(s)− Yi(s)dΛ∗(s;η)}
+ (1− w∗ηi)S∗T (s|gη(Xi),Xi)SC(s)d{Λ∗T (s|gη(Xi),Xi)− Λ∗(s;η)}.
Note that the first term in dhi(s) equals to w
∗
ηidM
∗
i {gη(X); s} and the second term is zero
if the propensity score model is correctly specified. If the survival model for T is correctly
specified, we have E{Λ∗T (s|gη(Xi),Xi)}−Λ∗(s;η) = 0. Define ψ1i(u;η) =
∫ u
0
dhi(s)
E[Y ∗{gη(X);s}] .
Then, ψ1i(u;η)’s are independent mean-zero processes. Let ψi(u;η) = ψ1i(u;η)+ψ2i(u;η).
We have
√
n{Λ̂A(u;η)−Λ∗(u;η)} = n−1/2
∑n
i=1 ψi(u;η)+op(1), which converges weakly to
a mean-zero Gaussian process. By Delta method,
√
n{ŜA(u;η)−S∗(u;η)} also converges
weakly to a mean-zero Gaussian process.
Following the proof for Theorem 1, we have
√
n{ŜA(t; ηˆoptA )− S∗(t;ηopt)} −
√
n{ŜA(t;ηopt)− S∗(t;ηopt)} = op(1).
It follows that
√
n{ŜA(t; ηˆoptA ) − S∗(t;ηopt)} →d N(0,ΣA(t;ηopt)), where ΣA(t;ηopt) =
{S∗(u;ηopt)}2E{ψ2i (u;ηopt)}.
Finally, for any given η, we have
√
n
{
Λ˜A(t;η)− Λ̂A(t;η)
}
=
√
n× 1
n
n∑
i=1
{
Φ
(
ηTXi
h
)
− I (ηTXi ≥ 0)}×KA1 (Xi, Ai, T˜i, δ;η) (A.6)
+
√
n× 1
n
n∑
i=1
{
Φ
(
ηTXi
h
)
− I (ηTXi ≥ 0)}×KA2 (Xi, Ai, T˜i, δ;η) (A.7)
+ op(1).
Under conditions A5 and A6, following the similar arguments in the proof for (iv) of
Theorem 1, (A.6) and (A.7) can be bounded uniformly in η. Therefore,
√
n{S˜A(t;η) −
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ŜA(t;η)} = op(1) uniformly in η. Since
√
n{S˜A(t; η˜optA ) − S˜A(t;ηopt)} = op(1) and√
n{ŜA(t; ηˆoptA )−ŜA(t;ηopt)} = op(1), it follows that
√
n{S˜A(t; η˜optA )−ŜA(t; ηˆoptA )} = op(1).
A.3 Proof of Theorem 3
To establish the asymptotic results given in Theorem 3, the regularity conditions A1-
A3 and A5-A6 need to be modified accordingly to incorporate the two-stage treatment
regimes, and condition A4 is not needed. However, the proof of Theorem 3 can follow
similar steps as for the proof of Theorem 1, and is omitted here.
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Table 1: Simulation results for the extreme value error distribution with n = 250 and t = 2.
PS ηˆ0 ηˆ1 ηˆ2 Sˆ(ηˆ
opt) SE CP S(ηˆopt) MR
Censoring Rate = 15%
SˆI T 0.008 (0.302) 0.631 (0.191) −0.666 (0.179) 0.645 (0.037) 0.040 0.839 0.590 (0.016) 0.118 (0.064)
S˜I T −0.005 (0.262) 0.653 (0.179) −0.666 (0.171) 0.612 (0.036) 0.040 0.968 0.593 (0.014) 0.107 (0.057)
SˆA T 0.006 (0.285) 0.639 (0.172) −0.675 (0.161) 0.639 (0.037) 0.041 0.882 0.592 (0.014) 0.109 (0.059)
S˜A T −0.002 (0.260) 0.654 (0.175) −0.670 (0.160) 0.610 (0.036) 0.041 0.970 0.593 (0.013) 0.104 (0.056)
SˆI F −0.026 (0.414) 0.413 (0.321) −0.702 (0.249) 0.666 (0.036) 0.039 0.657 0.566 (0.038) 0.190 (0.099)
S˜I F −0.051 (0.402) 0.427 (0.284) −0.714 (0.252) 0.643 (0.035) 0.039 0.844 0.569 (0.034) 0.184 (0.090)
SˆA F −0.013 (0.277) 0.661 (0.152) −0.662 (0.160) 0.635 (0.038) 0.041 0.889 0.593 (0.011) 0.106 (0.055)
S˜A F 0.001 (0.315) 0.616 (0.183) −0.669 (0.200) 0.612 (0.037) 0.042 0.966 0.589 (0.015) 0.126 (0.062)
Censoring Rate = 40%
SˆI T 0.004 (0.317) 0.615 (0.215) −0.659 (0.202) 0.650 (0.041) 0.044 0.848 0.587 (0.019) 0.128 (0.069)
S˜I T −0.002 (0.286) 0.637 (0.202) −0.660 (0.192) 0.613 (0.040) 0.045 0.958 0.590 (0.017) 0.118 (0.064)
SˆA T 0.003 (0.305) 0.621 (0.204) −0.664 (0.199) 0.645 (0.041) 0.046 0.892 0.589 (0.019) 0.124 (0.067)
S˜A T 0.002 (0.290) 0.642 (0.196) −0.656 (0.188) 0.612 (0.040) 0.046 0.966 0.590 (0.017) 0.118 (0.064)
SˆI F −0.002 (0.439) 0.394 (0.344) −0.677 (0.275) 0.671 (0.040) 0.043 0.678 0.561 (0.043) 0.204 (0.106)
S˜I F −0.024 (0.432) 0.404 (0.310) −0.694 (0.271) 0.645 (0.039) 0.043 0.867 0.564 (0.038) 0.199 (0.094)
SˆA F −0.005 (0.302) 0.652 (0.168) −0.650 (0.183) 0.641 (0.042) 0.046 0.894 0.591 (0.014) 0.116 (0.061)
S˜A F 0.011 (0.339) 0.606 (0.204) −0.655 (0.217) 0.615 (0.041) 0.046 0.961 0.586 (0.018) 0.138 (0.067)
† PS, the propensity score model. Here T means the correctly specified PS model while F means the misspecified PS
model. Recall that S(ηopt) = 0.605.
34
Table 2: Simulation results for the logistic error distribution with n = 250 and t = 2.
PS ηˆ0 ηˆ1 ηˆ2 Sˆ(ηˆ
opt) SE CP S(ηˆopt) MR
Censoring Rate = 15%
SˆI T 0.013 (0.374) 0.559 (0.277) −0.641 (0.246) 0.716 (0.034) 0.038 0.790 0.652 (0.023) 0.156 (0.092)
S˜I T −0.002 (0.340) 0.593 (0.259) −0.641 (0.235) 0.685 (0.034) 0.039 0.955 0.655 (0.020) 0.145 (0.081)
SˆA T 0.008 (0.360) 0.576 (0.257) −0.645 (0.235) 0.713 (0.034) 0.040 0.833 0.654 (0.020) 0.149 (0.084)
S˜A T −0.009 (0.343) 0.592 (0.256) −0.642 (0.233) 0.684 (0.034) 0.040 0.964 0.655 (0.020) 0.144 (0.082)
SˆI F 0.033 (0.462) 0.342 (0.388) −0.662 (0.284) 0.729 (0.033) 0.037 0.649 0.632 (0.039) 0.223 (0.119)
S˜I F −0.002 (0.460) 0.376 (0.350) −0.666 (0.285) 0.707 (0.033) 0.037 0.846 0.636 (0.034) 0.216 (0.107)
SˆA F −0.019 (0.336) 0.627 (0.203) −0.638 (0.213) 0.723 (0.036) 0.040 0.757 0.658 (0.013) 0.134 (0.068)
S˜A F −0.022 (0.353) 0.594 (0.224) −0.646 (0.234) 0.698 (0.035) 0.040 0.920 0.656 (0.015) 0.146 (0.070)
Censoring Rate = 40%
SˆI T 0.013 (0.385) 0.548 (0.293) −0.630 (0.261) 0.721 (0.036) 0.041 0.784 0.650 (0.026) 0.165 (0.095)
S˜I T −0.007 (0.361) 0.581 (0.273) −0.626 (0.256) 0.687 (0.036) 0.041 0.948 0.652 (0.022) 0.155 (0.087)
SˆA T 0.008 (0.379) 0.559 (0.277) −0.632 (0.261) 0.718 (0.036) 0.043 0.814 0.651 (0.023) 0.160 (0.090)
S˜A T −0.018 (0.360) 0.578 (0.271) −0.634 (0.247) 0.687 (0.036) 0.043 0.961 0.653 (0.022) 0.153 (0.086)
SˆI F 0.048 (0.472) 0.329 (0.411) −0.635 (0.307) 0.733 (0.035) 0.039 0.658 0.628 (0.042) 0.236 (0.125)
S˜I F 0.020 (0.481) 0.358 (0.367) −0.638 (0.314) 0.709 (0.035) 0.040 0.842 0.631 (0.038) 0.229 (0.113)
SˆA F −0.005 (0.349) 0.620 (0.207) −0.636 (0.217) 0.722 (0.038) 0.043 0.788 0.657 (0.015) 0.138 (0.071)
S˜A F −0.010 (0.376) 0.581 (0.239) −0.634 (0.250) 0.696 (0.038) 0.043 0.932 0.653 (0.016) 0.156 (0.074)
† PS, the propensity score model. Here T means the correctly specified PS model while F means the misspecified PS
model. Recall that S(ηopt) = 0.672.
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Table 3: Simulation results for estimating optimal dynamic treatment regimes.
C% S ηˆopt1 ηˆ
opt
2 ηˆ
opt
3 ηˆ
opt
4 Sˆ(ηˆ
opt) SE CP S(ηˆopt) MR
Senario 1: ηopt = (0.890,−0.456, 0.894,−0.447);S(3;ηopt) = 0.567
15 F 0.882 (0.035) −0.466 (0.062) 0.893 (0.016) −0.449 (0.032) 0.591 (0.028) 0.030 0.885 0.559 (0.008) 0.105 (0.054)
T 0.884 (0.028) −0.463 (0.052) 0.894 (0.013) −0.448 (0.026) 0.570 (0.028) 0.030 0.955 0.561 (0.006) 0.088 (0.048)
40 F 0.880 (0.041) −0.469 (0.071) 0.890 (0.022) −0.453 (0.041) 0.600 (0.036) 0.037 0.841 0.556 (0.011) 0.124 (0.061)
T 0.883 (0.03) −0.463 (0.061) 0.892 (0.018) −0.450 (0.035) 0.574 (0.035) 0.038 0.955 0.558 (0.009) 0.108 (0.056)
Senario 2: ηopt = (−0.891, 0.454, 0.894,−0.447);S(6;ηopt) = 0.624
15 F −0.888 (0.025) 0.456 (0.044) 0.891 (0.018) −0.451 (0.034) 0.645 (0.025) 0.027 0.890 0.616 (0.008) 0.097 (0.051)
T −0.889 (0.018) 0.456 (0.034) 0.893 (0.014) −0.450 (0.028) 0.624 (0.024) 0.027 0.967 0.618 (0.005) 0.079 (0.042)
40 F −0.886 (0.028) 0.460 (0.051) 0.891 (0.020) −0.453 (0.037) 0.650 (0.027) 0.029 0.857 0.614 (0.009) 0.108 (0.054)
T −0.888 (0.022) 0.457 (0.040) 0.892 (0.016) −0.450 (0.032) 0.626 (0.027) 0.030 0.972 0.617 (0.007) 0.091 (0.048)
Senario 3: ηopt = (0.908,−0.419, 0.894,−0.447);S(3;ηopt) = 0.702
15 F 0.898 (0.037) −0.433 (0.068) 0.892 (0.020) −0.450 (0.038) 0.728 (0.026) 0.027 0.829 0.693 (0.009) 0.132 (0.067)
T 0.900 (0.031) −0.430 (0.060) 0.893 (0.016) −0.448 (0.031) 0.707 (0.026) 0.027 0.952 0.695 (0.007) 0.115 (0.060)
40 F 0.897 (0.040) −0.435 (0.074) 0.891 (0.022) −0.452 (0.042) 0.732 (0.028) 0.029 0.808 0.691 (0.011) 0.140 (0.074)
T 0.899 (0.035) −0.431 (0.065) 0.893 (0.018) −0.449 (0.036) 0.709 (0.028) 0.030 0.951 0.693 (0.008) 0.125 (0.065)
†C% denotes the censoring rate; S indicates whether the smoothing technique is applied (T) or not (F).
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Table 4: Estimation results for the AIDS data.
t Method Intercept Karnof CD40 Age S˜(t; η˜opt)
400 I -0.143 -0.355 0.025 0.924 0.965 (0.008)
A -0.660 -0.265 0.020 0.703 0.965 (0.008)
600 I 0.908 -0.147 0.002 0.391 0.923 (0.012)
A 0.998 -0.026 -0.000 0.050 0.923 (0.012)
800 I 0.815 -0.154 -0.011 0.558 0.887 (0.014)
A 0.882 -0.127 -0.009 0.453 0.886 (0.014)
1000 I 0.067 -0.192 -0.035 0.978 0.824 (0.017)
A -0.619 -0.140 -0.029 0.772 0.823 (0.018)
†I denotes the IPSWKME and A denotes the AIPSWKME; the numbers in the parenthesis are the estimated standard
errors.
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Table 5: Confidence intervals for comparing estimated optimal treatment regimes and
simple regimes.
Norm CI Boot CI
t Method trt 1 trt 0 trt 1 trt 0
400 I (−0.002, 0.022) (−0.003, 0.044) (0.003, 0.029) (0.007, 0.045)
A (−0.002, 0.022) (−0.003, 0.043) (0.003, 0.028) (0.006, 0.044)
600 I (0.001, 0.044) (−0.006, 0.051) (0.013, 0.055) (0.010, 0.054)
A (0.003, 0.042) (−0.007, 0.052) (0.011, 0.053) (0.008, 0.054)
800 I (0.008, 0.057) (−0.001, 0.068) (0.014, 0.066) (0.009, 0.069)
A (0.007, 0.056) (−0.003, 0.067) (0.012, 0.064) (0.008, 0.069)
1000 I (0.006, 0.059) (−0.005, 0.080) (0.010, 0.076) (0.014, 0.083)
A (0.004, 0.058) (−0.006, 0.079) (0.010, 0.072) (0.010, 0.082)
†I denotes the IPSWKME and A denotes the AIPSWKME; trt represents treatment;
Norm CI denotes the confidence interval obtained using normal approximation based on
asymptotic results; Boot CI denotes the confidence interval obtained using 500
bootstraps.
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